Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jun 28;9:1510. doi: 10.3389/fimmu.2018.01510

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2018 Kubo, Nakayamada, Sakata, Kitanaga, Ma, Lee, Ishii, Yamagata, Nakano and Tanaka.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Baricitinib suppresses type-I interferon (IFN) production from plasmacytoid dendritic cells (pDCs). Peripheral blood mononuclear cells were stimulated with toll-like receptor (TLR) 9 agonist with or without baricitinib and other inhibitors. TLR9-mediated cytokine production by pDCs (Lin⁻HLA-DR⁺ CD11c⁻CD123⁺ cells) was measured by intracellular staining or ELISA. (A) Percentage of TNF-α- and IFN-α-producing pDCs. (B) Representative flow cytometry plots showing IFN-α production by pDCs. (C) IFN-α concentration in the supernatants. (D) Percentage of TNF-α- and IFN-α-producing pDCs in the presence of baricitinib and other inhibitors. (E) Representative histogram data of annexin V/propidium iodide staining from three independent experiments. (F) Expression of CD80 and CD86 on pDCs. Data are mean ± SD of three different donors per group. *p < 0.05 (by Student’s t-test).